Clinical trial
Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV…
NCT00466817 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00466817 |
|---|---|
| Title | Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections |
| Official title | A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112) |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Cytomegalovirus Infection |
| Intervention type | Drug, Other |
| Interventions | Placebo, Valganciclovir |
| Enrollment | 109 |
| Start date | Jun 1, 2008 |
| Primary completion | Dec 1, 2011 |
| Completion | Jun 1, 2013 |
| First posted | Apr 27, 2007 |
| Last update posted | Aug 26, 2015 |
| Countries | United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: